A Randomized Controlled Phase Ill Clinical Study of BL-M07D1 for Injection Versus Trastuzumab Emtansine (T-DM1) in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Latest Information Update: 24 Feb 2025
At a glance
- Drugs BL-M07D1 (Primary) ; Trastuzumab emtansine
- Indications HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 24 Feb 2025 New trial record